ClinicalTrials.gg
Active, not recruitingNCT04446351Updated Oct 27, 2025

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of GSK6097608 and Dostarlimab in Neoplasms, sponsored by GlaxoSmithKline. Active, not recruiting at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy (Arm D); and in combination with belrestotug (Arm E); and with GSK6097608 + belrestotug (Arm F) in Japanese and Chinese participants. The study may assess the PK/PD cohorts for Arm E and/or Arm F in participants outside of China and Japan. Additionally, dostarlimab will be given in combination with cobolimab in Japanese participants. Drug name mentioned as belrestotug, GSK4428859A and EOS884448 are interchangeable for the same compound. In the rest of the document, the drug will be referred to as belrestotug.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • GSK6097608
  • dostarlimab
  • Dose escalation
  • Pharmacokinetics
  • Pharmacodynamics
  • Advanced solid tumors
  • First-time-in-human
  • GSK4428859A
  • EOS884448
  • cobolimab
  • belrestotug
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 107 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years of age or older (or >=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan)
  • Female participants of must agree to use a highly effective form of
  • Histological or cytological documentation of locally advanced, recurrent, or solid . Enrollment in PK/PD cohorts will be restricted to participants with or cytologically confirmed diagnosis of 1 or more of the following: non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer (EC), colorectal cancer (CRC) (including specified molecular subtypes of these) or an alternative immunogenic tumor type with medical monitor approval
  • Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists
  • Participants in a PK/PD cohort (Arms A, B, E and F) must provide fresh tumor . Biopsies are not required from participants enrolled in Arm D, Arm E, (non-PK/PD cohorts only), Arm F (non-PK/PD cohort only), Arm G or any participant enrolled in mainland China
  • (ECOG) performance status (PS) 0 to 1
  • of at least 12 weeks
  • Adequate organ function as determined by laboratory assessments
  • Adequate cardiac as measured by echocardiogram
  • Arm A-Japan, Arm D-Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese
  • Arm A-China, Arm B-China, Arm D-China, Arm E-China and Arm F-China only (excluding PK/PD cohorts in Arm E and Arm F): is of Chinese descent and lives in China
  • Arm D, Arm E, Arm F, and Arm G only: has been deemed suitable for assigned treatment based on assessment by the investigator

Exclusion criteria

Exclusion Criteria:

  • Prior anti-cancer treatment including agents, , chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter
  • Prior allogenic or bone marrow transplantation or other solid organ transplantation
  • Toxicity from previous anticancer treatment, including; greater than or equal to (>=) Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved; or history of myocarditis of any grade during a previous treatment with immunotherapy
  • Known additional that progressed or required active treatment within the last 2 years
  • Uncontrolled or symptomatic central nervous system (CNS) and/or carcinomatous meningitis
  • Active disease that has required systemic disease-modifying or treatment within the last 2 years
  • Concurrent medical condition requiring the use of systemic immunosuppressive treatment
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment
  • Active infection requiring systemic treatment, known infection, or positive test for surface antigen (HBsAg) or virus (HCV)
  • Prolonged as measured by
  • Allergen desensitization therapy within 4 weeks of starting study intervention
  • History of to any of the study interventions or their
  • Has a history or evidence of cardiac abnormalities within the 6 months prior to enrolment
  • Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions
  • History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing pneumonia; noninfectious pneumonitis that required , or evidence of active, noninfectious pneumonitis
  • Pregnant or lactating woman
  • Receipt of within 30 days of the start of study intervention
  • Receipt of transfusion of blood products or administration of colony-stimulating factors within 14 days before the first dose of study intervention
  • Major surgery less than 4 weeks before the first dose of study intervention
  • Known drug or alcohol abuse
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Participants receiving GSK6097608 monotherapy (Arm A)

    Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.

    Drug: GSK6097608

  • Experimental
    Participants receiving GSK6097608 plus dostarlimab (Arm B)

    Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.

    Drug: GSK6097608 · Drug: Dostarlimab

  • Experimental
    Participants receiving dostarlimab monotherapy (Arm D)

    Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).

    Drug: Dostarlimab

  • Experimental
    Participants receiving dostarlimab plus belrestotug (Arm E)

    Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks.

    Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F)

    Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks.

    Drug: GSK6097608 · Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Participants receiving dostarlimab plus cobolimab (Arm G)

    Participants will be administered an IV infusion of cobolimab followed by dostarlimab

    Drug: Dostarlimab · Drug: Cobolimab

Interventions

  • GSK6097608 will be administered as an IV infusion.

  • Dostarlimab will be administered as an IV infusion.

  • Cobolimab will be administered as an IV infusion.

  • Belrestotug will be administered as an IV infusion.

    Also known as: GSK4428859A, EOS884448

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to Day 21

  2. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 2 years

Secondary outcomes

  1. Number of participants with clinically significant changes in laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) findings

    Time frame: Up to 2 years

  2. Number of participants with dose reductions or delay

    Time frame: Up to 2 years

  3. Number of participants withdrawn due to AEs

    Time frame: Up to 2 years

  4. Overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Up to 2 years

  5. Arms D, E, F, G: ORR based on modified Response Evaluation Criteria in Solid Tumors (iRECIST)

    Time frame: Up to 2 years

  6. Arms D, E, F, G: Disease Control Rate (DCR) based on RECIST 1.1

    Time frame: Up to 2 years

  7. Arms D, E, F, G: DCR based on iRECIST

    Time frame: Up to 2 years

  8. Arms D, E, F, G: Time to response (TTR) based on RECIST 1.1

    Time frame: Up to 2 years

  9. Arms D, E, F, G: TTR based on iRECIST

    Time frame: Up to 2 years

  10. Arms D, E, F, G: Duration of response (DOR) based on RECIST 1.1

    Time frame: Up to 2 years

  11. Arms D, E, F, G: DOR based on iRECIST

    Time frame: Up to 2 years

  12. Arms D, E, F, G: Progression-free survival (PFS) based on RECIST 1.1

    Time frame: Up to 2 years

  13. Arms D, E, F, G: PFS based on iRECIST

    Time frame: Up to 2 years

  14. Arms A, B, F: Number of participants with positive anti-drug antibodies (ADAs) against GSK6097608

    Time frame: Up to 2 years

  15. Arms A, B, F: Titers of ADAs against GSK6097608

    Time frame: Up to 2 years

  16. Arms B, D, E, F, G: Number of participants with positive ADAs against dostarlimab

    Time frame: Up to 2 years

  17. Arms B, D, E, F, G: Titers of ADAs against dostarlimab

    Time frame: Up to 2 years

  18. Arms E, F: Number of participants with positive ADAs against belrestotug

    Time frame: Up to 2 years

  19. Arms E, F: Titers of ADAs against belrestotug

    Time frame: Up to 2 years

  20. Arm G: Number of participants with positive ADAs against cobolimab

    Time frame: Up to 2 years

  21. Arm G: Titers of ADAs against cobolimab

    Time frame: Up to 2 years

  22. Arms A, B, F: Maximum observed concentration (Cmax) for GSK6097608

    Time frame: Up to 2 years

  23. Arms A, B, F: Minimum observed concentration (Cmin) for GSK6097608

    Time frame: Up to 2 years

  24. Arms A, B, F: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) for GSK6097608

    Time frame: Up to 2 years

  25. Arms A, B, F: Area under the plasma concentration-time curve from time zero to time (AUC[0-t]) for GSK6097608

    Time frame: Up to 2 years

  26. Arms A, B, F: Apparent terminal phase half-life (t1/2) for GSK6097608

    Time frame: Up to 2 years

  27. Arms B, D, E, F, G: Cmax for dostarlimab

    Time frame: Up to 2 years

  28. Arms B, D, E, F, G: Cmin for dostarlimab

    Time frame: Up to 2 years

  29. Arms B, D, E, F, G: AUC(0-infinity) for dostarlimab

    Time frame: Up to 2 years

  30. Arms B, D, E, F, G: AUC(0-t) for dostarlimab

    Time frame: Up to 2 years

  31. Arms B, D, E, F, G: t1/2 for dostarlimab

    Time frame: Up to 2 years

  32. Arms E, F: Cmax for belrestotug

    Time frame: Up to 2 years

  33. Arms E, F: Cmin for belrestotug

    Time frame: Up to 2 years

  34. Arms E, F: AUC(0-infinity) for belrestotug

    Time frame: Up to 2 years

  35. Arms E, F: AUC(0-t) for belrestotug

    Time frame: Up to 2 years

  36. Arms E, F: t1/2 for belrestotug

    Time frame: Up to 2 years

  37. Arm G: Cmax for cobolimab

    Time frame: Up to 2 years

  38. Arm G: Cmin for cobolimab

    Time frame: Up to 2 years

  39. Arm G: AUC(0-infinity) for cobolimab

    Time frame: Up to 2 years

  40. Arm G: AUC(0-t) for cobolimab

    Time frame: Up to 2 years

  41. Arm G: t1/2 for cobolimab

    Time frame: Up to 2 years

07

Study locations

11 sites
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Houston, Texas 77030-4009, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1Z5, Canada
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Seoul, 06351, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2026, 78 months after the start.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 78 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2020
First posted
Jun 24, 2020
StartActual
Jun 25, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04446351
Lead sponsor
GlaxoSmithKline
Collaborators
23andMe, Inc., iTeos Therapeutics
Responsible party
Sponsor
First posted
Jun 24, 2020
Start date
Jun 25, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 27, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nelistotug · Cobolimab · Belrestotug

Start the discussion